Preclinical studies have shown MPNST dependence on the MAPK pathway6, but clinical efficacy with inhibition of MAPK kinase (MAP2K or MEK) has not been reported to date. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.